Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Robert Rosen

Surgery Wilmette, IL Medical Doctor

NPI 1639187719 CMS profile 1297252

3201 Old Glenview Rd Ste 130, Wilmette, IL 60091

Open in the dashboard

General payments

$1,900

45 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Robert Rosen of Wilmette, IL is reported in the CMS Open Payments database as having received $1,900 across 45 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 53rd percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $518 9
2023 General $255 7
2022 General $232 6
2021 General $112 6
2020 General $52 3
2019 General $731 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Rosen
  • Surgery median
  • Middle half of Surgery
  • National median

In program year 2025, general payments to Robert Rosen were reported at $0. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.

Show as a table
Year Robert Rosen Surgery median Middle half National median
2019 $731 $253 $82–$1,521 $163
2020 $52 $131 $40–$706 $114
2021 $112 $168 $50–$904 $132
2022 $232 $224 $76–$1,218 $149
2023 $255 $253 $82–$1,255 $160
2024 $518 $279 $90–$1,381 $164
2025 $0 $280 $91–$1,259 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Intuitive Surgical, Inc. $356 6 payments
  2. Smith+Nephew, Inc. $279 5 payments
  3. Ethicon US, LLC $220 4 payments
  4. Braintree Laboratories, Inc. $204 6 payments
  5. Carl Zeiss Meditec, Inc. $192 1 payment
  6. Baxter Healthcare $140 2 payments
  7. Focal Therapeutics, Inc. $135 1 payment
  8. W. L. Gore & Associates, Inc. $81 5 payments
  9. Kerecis Limited $43 1 payment
  10. Pacira Pharmaceuticals Incorporated $35 2 payments
  11. Other $216 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $1,284 40 payments
  2. Education $314 1 payment
  3. Gift $162 2 payments
  4. Travel and Lodging $140 2 payments
Products named General payments · program years 2019–2024
  1. Da Vinci Surgical System $356 6 payments
  2. IORT $192 1 payment
  3. Enseal $164 2 payments
  4. PERCLOT $140 2 payments
  5. BioZorb $135 1 payment
  6. Localizer $135 1 payment
  7. Stravix $127 3 payments
  8. SUTAB $122 5 payments
  9. PICO Single Use Negative Pressure Wound Therapy $116 1 payment
  10. GrafixPL $112 3 payments
  11. Other $774 31 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

720

Median for General Surgery: 59

Drug cost

$14,917

Median for General Surgery: $393

Branded share of claims

15.6%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dexlansoprazole Dr Dexlansoprazole Brand 14 $5,118
Famotidine Generic 381 $3,253
Sutab Sod Sulf/Pot Chloride/Mag Sulf Brand 12 $1,960
Sucralfate Generic 57 $1,461
Omeprazole Generic 137 $900
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 12 $867
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 56 $797
Peg-3350 And Electrolytes Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 18 $296
Cephalexin Generic 18 $137
Pantoprazole Sodium Generic 15 $127

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 49 billing codes

Paid by Medicare

$104,128

Medicare's payments for the services billed

Medicare patients

316

Average age 75

Services billed

823

186 women, 130 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 59%
Diabetes 39%
Ischemic heart disease 35%
Osteoporosis 30%
Cancer 28%
Depression 24%
Chronic kidney disease 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

45 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record